The Latest Breaking News from CMPX

Momentum investors seek to take advantage of share price rallies to buy companies before they peak; analysts think these three firms still have room to grow.

The oncology industry is expected to grow considerably in 2022, driven by the rising occurrence of cancer in the U.S. population. Furthermore, increasing investments by biopharmaceutical companies and the government should fuel the industry's growth. Given the industry's bright growth prospects, Wall Street analysts expect the stocks of quality oncology…